品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com

academy biomed/[P27] 4 Hydroxynonenal modified Bovine Serum Albumin (4 HNE-BSA)/1.0 mg/40P-HNE-BS110

价格
¥8400.00
货号:40P-HNE-BS110
浏览量:127
品牌:academy biomed
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Concentration:1 mg / ml, determined by the Lowry method
Source:Bovine Serum Albumin purchased from Boehringer Mannheim and modified with 4- HNE.
Buffer:In 10 mM PBS, 0.15 M NaCl, 0.5 mM EDTA, 0.01 % NaN3, pH 7.4.
Storage:-20°C for short and long-term storage. Aliquot to avoid repeated freezing and thawing.

 

*The products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

 

Importance

Modifications on lysine residues, with formation of carboxylmethyl-lysine (CML), malondialdehyde (MDA) and hexitol-lysine are advanced glycation end-products (AGE), and the coupling with reactive aldehyde compounds, such as 4-hydroxynonenal (4-HNE) may appear from lipid oxidation (Guichardant et al., 1998). These modifications feature the oxidative byproducts which react with NH2 groups and form Schiff-base adducts (Mark et al., 1996).

LDL treated with HNE or oxidatively modified by Cu++ or by cultured endothelial cells give rise to Michael addition-type HNE adducts that are recognized by HNE-specific antibodies.

Guichardant M, Taibi-Tronche P, Fay LB, Lagarde M. Covalent modifications of aminophospholipids by 4-hydroxynonenal. Free Radic Biol Med. 1998 Dec;25(9):1049-56.

Mark S. Bolgar, Chao-Yuh Yang, and Simon J. Gaskell, First Direct Evidence for Lipid/Protein Conjugation in Oxidized Human Low Density Lipoprotein (LDL), JBC, 271: 27999-28001 (1996).

 

Citations

[P27]2017Grönwall, Caroline; Amara, Khaled; Hardt, Uta; Krishnamurthy, Akilan; Steen, Johanna; Engström, Marianne et al. (2017): Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis. In Journal of autoimmunity 84, pp. 29–45. DOI: 10.1016/j.jaut.2017.06.004.
academy biomed[A05]绵羊抗人类载脂蛋白AII多克隆抗体12A-S1a学院生物医学公司$ 155.00$ 155.00目录号数量1寄主物种: 羊浓度: 1毫克/毫升(OD 1.35 / 280 nm)抗原: 人类载脂蛋白AII纯化: 亲和纯化缓冲: 75 mM磷酸钠,75 mM NaCl,0.5 mM EDTA,0.02%NaN3,pH 7.2特异性 与人载脂蛋白AII特异性结合。免疫印迹和ELISA的稀释范围:1,000至80,000。用: 该抗体可用于检测血浆和脂蛋白中的载脂蛋白AII,免疫测定,免疫印迹,酶结合或生物素化。存储: -20°C长期保存,4°C短期保存。等分试样,以避免反复冻结和解冻。 *这些产品仅用于研究或制造用途,不能用于人体治疗或诊断应用。 重要性Apo AII占HDL的25%。它在人血浆中以77条氨基酸残基的2条相同链的二聚体形式存在,并通过二硫键连接。据报道,单链的分子量为8.7kDa(Brewer等,1972)。对小鼠的研究报道,apoAII可能具有促动脉粥样硬化作用(Warden等,1993)。然而,一项大型的欧洲前瞻性研究中的病例对照研究表明,血浆Apo AII浓度与冠心病事件密切相关(Birjmohun等,2007)。Birjmohun,RS,GM Dallinga-Thie,JA Kuivenhoven,ESg Stroes,JD Otvos,NJ Wareham,R.Luben,JJp Kastelein,K.-T. Khaw和SM Boekholdt。“载脂蛋白A-II与未来冠状动脉疾病的风险成反比。” 循环116(2007):2029-035。Brewer,HB,SE Lux,R.Ronan和KM John。“人ApoLp-Gln-II(apoA-II),一种从高密度脂蛋白复合物中分离的载脂蛋白的氨基酸序列。” 美国国家科学院院刊69.5(1972):1304-308。Warden,C.,C.Hedrick,J.Qiao,L.Castellani和A.Lusis。“过表达载脂蛋白A-II的转基因小鼠中的动脉粥样硬化。” 科学261(1993):469-72。